Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver transplant study tests best way to manage fluids during surgery

NCT ID NCT05647733

Knowledge-focused Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study compares two approaches to giving fluids during liver transplant surgery: a restrictive strategy that removes some blood early and returns it later, versus a liberal strategy that keeps blood flow high. The goal is to see if a larger study is possible by checking recruitment rates and how well doctors follow the plan. About 138 adults with end-stage liver disease will take part across four Canadian hospitals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could show which fluid management method is safer for liver transplant patients and pave the way for a larger, definitive trial.
What could go wrong
This is a small pilot study focused on feasibility, not on proving which strategy is better. Results may not apply to all patients or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 138 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any adult patient ≥ 18 years of age undergoing liver transplantation for ESLD. Exclusion Criteria: * Patients undergoing LT for an indication other than ESLD such as acute liver failure, liver cancer without ESLD, retransplantation, amyloid neuropathy or any other indication not associated with ESLD. * Patients undergoing a combined liver and lung or liver and heart transplantation. * Patients with any of the following conditions: * severe chronic renal failure (GFR \< 15 ml/minute/1.73 m2 \[CKD-EPI equation\] or already on RRT); * severe anemia (hemoglobin level \< 80 g/L);76,93,109 * hemodynamic instability (norepinephrine equivalent \> 10 ug/min).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure End Stage Liver Disease liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage liver disease (ESLD) Liver transplantation

Contacts and locations

Locations

  • Centre Hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec, H2X 0C1, Canada

  • London Health Sciences Centre

    London, Ontario, N6G 2V4, Canada

  • McGill University Health Centre

    Montreal, Quebec, H4A 3J1, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.